Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

According to the World Cancer Research Fund International, approximately 968,784 new cases of gastric cancer were diagnosed in 2022 across the globe. Data suggests that gastric cancer ranks among the top three most common cancers in 19 countries and continues to be the leading cause of cancer mortality worldwide. The ongoing development of innovative and novel therapies shows a promising future for gastric cancer treatment.

Report Coverage

The Gastric Cancer Pipeline Report by Expert Market Research gives comprehensive insights on the gastric cancer emerging drugs currently undergoing clinical trials and covers various aspects related to the details for each of these drugs under development. The gastric cancer report insights include the analysis of over 100 pipeline drugs and 50+ companies. Moreover, the analysis based on efficacy and safety measure outcomes published for the trials will be covered including their adverse effects in gastric cancer.

A detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing gastric cancer pipeline development activities are covered.

Gastric Cancer Drug Pipeline Outlook

An abnormal cell growth in the stomach can lead to gastric cancer. Before the development of true cancer, pre-cancerous changes occur in the inner lining of the stomach. There are multiple types of gastric cancer which include adenocarcinoma of the stomach, Gastroesophageal Junction Adenocarcinoma (GEJ), gastrointestinal neuroendocrine tumors, and Gastrointestinal Stromal Tumors (GIST).

Gastric cancer treatment depends on the location of the cancer within the stomach and cancer stage. The treatment options include chemotherapy, targeted therapy and immunotherapy, radiation therapy and others. In 2021, the U.S. Food and Drug Administration amended its accelerated approval of the immu notherapy drug pembrolizumab (Keytruda) for treatment of advanced stomach cancer and gastroesophageal junction (GEJ) cancer.

Research studies shows that the drugs that target HER2 can be used to treat other cancers as well stomach cancer and GEJ cancer. Data suggests that 15% of patients with advanced stomach cancer have HER2-positive tumors. In November 2023, the U.S. Food and Drug Administration approved pembrolizumab combined with chemotherapy as an initial treatment for patients suffering from advanced stomach gastric that is HER2-negative.

The gastric cancer report covers the pathophysiology and epidemiology of gastric cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for treatment in detail.

Gastric Cancer – Drug Pipeline Therapeutic Assessment

This section of the gastric cancer pipeline report covers the analysis of gastric cancer drugs based on various segmentations such as:

By Phase

EMR’s pipeline assessment report covers 50+ drug analysis based on phase.

  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Route of Administration

EMR’s gastric cancer report assessment report covers 50+ drug analysis based on route of administration.

  • Oral
  • Parenteral
  • Others

Gastric Cancer – Pipeline Assessment Segmentation, By Phases

The gastric cancer pipeline landscape covers phase I, phase II, phase III, phase IV, and early phase drugs for Gastric cancer. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II trials cover major share of the total gastric cancer clinical trials conducted.

Nivolumab developed by Bristol-Myers Squibb is currently under phase II. The purpose of the study is to assess the safety and efficacy of Nivolumab in combination with Ipilimumab for the treatment of advanced gastric cancer.

Gastric Cancer – Pipeline Assessment Segmentation, By Route of Administration

The route of administration categories covered under gastric cancer clinical assessment include oral, parenteral and others. The report covers a comparative analysis of the route of administration for each drug in various phases of clinical trials of gastric cancer. According to EMR analysis, the parenteral route accounted for a major share of gastric cancer clinical trials.

Gastric Cancer – Pipeline Assessment – Competitive Dynamics

The EMR report for the gastric cancer drug pipeline insight covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in gastric cancer clinical trials:

  • Bristol-Myers Squibb
  • AstraZeneca
  • Enzon Pharmaceuticals, Inc.
  • Amgen
  • Novartis Pharmaceuticals
  • Bayer AG
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Others

Gastric Cancer – Emerging Drugs Profile

The EMR gastric cancer drug profiles cover the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for gastric cancer. Moreover, the section covers product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.

Bemarit uzumab - Amgen

Amgen is conducting phase I clinical trials for bemarituzumab. The purpose of the study is to evaluate the safety and efficacy of bemarituzumab in combination with other anti-cancer therapies to treat multiple cancers including gastric cancer.

Everolimus - Novartis Pharmaceuticals

The purpose of the study is to evaluate the efficacy and safety of gastric cancer drug candidate RAD001 (Everolimus) monotherapy in patients suffering from advanced gastric cancer.

Trastuzumab - Hoffmann-La Roche

The study is under the observational phase and is sponsored by Hoffmann-La Roche. The primary purpose of the study is to evaluate Human HER-2 status in gastric cancer.

DS-8201a (DP1) - Daiichi Sankyo Co., L td.

Daiichi Sankyo Co., Ltd. Is conducting phase I trial to assess the safety of DS-8201a in participants suffering from advanced solid malignant tumors.

*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*

Key Questions Answered in the Gastric Cancer – Pipeline Assessment Report

  • What is the current landscape of gastric cancer pipeline drugs?
  • Which companies/institutions are developing gastric cancer therapeutic drugs?
  • How many phase II drugs are currently present in gastric cancer pipeline drugs?
  • Which company is leading the gastric cancer pipeline development activities?
  • What is the current gastric cancer commercial assessment?
  • What are the opportunities and challenges present in the gastric cancer drug pipeline landscape?
  • What is the efficacy and safety profile of gastric cancer pipeline drugs?
  • Which companies/institutions are involved in gastric cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in gastric cancer?

Related Reports

Global Gastric Ulcer Treatment Market

North America Gastric Cancer Drugs Market

Global Cancer Therapeutics Market

Global Cancer Immunotherapy Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report Details
Drug Pipeline by Clinical Trial Phase
  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products 
Route of Administration
  • Oral
  • Parenteral
  • Others
Drug Classes
  • Monoclonal Antibody
  • Recombinant Fusion Proteins
  • Small Molecule
  • Gene Therapy 
  • Peptide
  • Polymer
Treatment Type
  • Chemotherapy
  • Immunotherapy
  • Hormone Therapy
  • Targeted Therapy
  • Others
Leading Sponsors Covered
  • Bristol-Myers Squibb
  • AstraZeneca
  • Enzon Pharmaceuticals, Inc.
  • Amgen
  • Novartis Pharmaceuticals
  • Bayer AG
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Hoffmann-La Roche
  • Others
Geographies Covered
  • North America
  • Europe
  • Asia Pacific
  • Others

Mini Report

10 % Off

USD

1,999

1,799

Single User License

10 % Off

USD

3,099

2,789

Five User License

15 % Off

USD

4,599

3,909

Corporate License

15 % Off

USD

5,999

5,099

Mini Report

One User

USD 1,999

USD 1,799

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 3,099

USD 2,789

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 4,599

USD 3,909

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 5,999

USD 5,099

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-723-689-1189

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-723-689-1189

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124